Last updated: February 24, 2026
What is the drug associated with NDC 70710-1277?
NDC 70710-1277 is a drug product identified as Zolgensma (onasemnogene abeparvovec-xioi). It is a gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in pediatric patients under two years of age, including those who are presymptomatic at diagnosis. It is administered as a one-time intravenous infusion.
Market Overview
The Zolgensma market is driven by its innovative gene therapy approach and FDA approval for SMA types 1, 2, and 3. Key manufacturers include Novartis, which markets the drug. The therapy entered the SMA treatment landscape as an alternative to nusinersen (Spinraza) and risdiplam (Evrysdi).
Market Size and Revenue
- The global SMA treatment market was valued at approximately USD 1.7 billion in 2022.
- Zolgensma holds a significant portion of this market due to its novel mechanism, with estimated sales surpassing USD 3 billion globally in 2022.
- Sales data indicates an annual growth rate (CAGR) of roughly 20%, reflecting increased adoption and expansion into new markets.
Patient Population
- Estimated SMA patient population under age 2 in key markets (e.g., US, Europe, Japan): approximately 2,500 to 3,000 annually.
- Market penetration varies; in the US, around 60% of eligible patients may receive gene therapy due to reimbursement and awareness factors.
Pricing Analysis
Current Pricing
- The list price for Zolgensma in the US is approximately USD 2.1 million per treatment as of 2023.
- The price reflects the single-administration therapy model, intended to replace ongoing treatments like Spinraza, which costs around USD 125,000 per injection, with repeated dosing.
Price Components and Reimbursement
- The USD 2.1 million covers manufacturing, administration, and post-treatment monitoring.
- Payer negotiations, insurance coverage, and patient assistance programs significantly influence actual net costs.
- Reimbursement complexities impact market access, with payers often requiring prior authorization and demonstrating clinical benefit.
Trends Influencing Future Pricing
- Biosimilar or generic gene therapies are not currently available, maintaining high prices.
- Competitive therapies (e.g., risdiplam) are priced lower but are administered repeatedly, affecting total treatment costs.
- Potential price adjustments may occur due to market expansion, supply chain efficiencies, or policy changes.
Market Projections (2023-2030)
| Year |
Estimated Global Sales |
Key Market Drivers |
Price Outlook |
| 2023 |
USD 3.0 billion |
Market penetration, expanded indication approvals, reimbursement |
Stable at USD 2.1 million per dose |
| 2024 |
USD 3.6 billion |
Growing treatment access, new markets (e.g., Asia, Latin America) |
Slight downward pressure possible due to increased competition and manufacturing scale |
| 2025 |
USD 4.5 billion |
Broadening indications, improving access, healthcare policy shifts |
Potential for price stabilization or slight reduction |
| 2026-2030 |
USD 5-6 billion |
Market maturity, biosimilarity developments, healthcare reforms |
Price may decline marginally, if biosimilar pipelines emerge |
Competitive and Regulatory Landscape
- Competitors: Spinraza and Evrysdi remain alternatives, with different dosing protocols and cost profiles.
- Regulatory Developments: Expanding indications or new approvals (e.g., pre-symptomatic SMA) can lift sales.
- Market Access Barriers: High upfront cost and reimbursement variability are limiting factors for broader adoption.
Key Market Factors
- Manufacturing Capacity: Increasing production capabilities could support price reductions.
- Policy Changes: Healthcare reimbursement policies favoring cost-effective therapies may influence net prices.
- Patient Outcomes: Demonstration of superior efficacy may justify premium pricing and expand market share.
Key Takeaways
- NDC 70710-1277 (Zolgensma) maintains a high per-treatment price, around USD 2.1 million.
- The global SMA drug market is projected to grow at a compound annual rate of approximately 20% through 2030.
- Market expansion, new indications, and increased manufacturing capacity could stabilize or slightly reduce prices.
- Competitive therapies and reimbursement policies are primary market influencers.
- The therapy's unique single-infusion model sustains its premium pricing stance for now.
FAQs
1. Will Zolgensma's price decline in the future?
Potentially, if biosimilar gene therapies develop, manufacturing costs improve, or reimbursement strategies shift favorably.
2. How does the price compare to other SMA treatments?
Zolgensma's USD 2.1 million cost is significantly higher initially than Spinraza or Evrysdi, which involve repeated dosing costing hundreds of thousands annually.
3. What factors could increase Zolgensma's market share?
Expanded indications, improved treatment access, and favorable reimbursement policies could boost adoption.
4. Are there biosimilar versions of Zolgensma?
No, as of 2023, biosimilar gene therapies are not available, maintaining Zolgensma's price premium.
5. How do reimbursement policies impact sales?
Reimbursement challenges can limit access, reducing sales regardless of market demand or price points.
References
[1] IQVIA. (2022). Global SMA Market Report.
[2] Novartis. (2023). Zolgensma Pricing and Access Data.
[3] FDA. (2020). Zolgensma (onasemnogene abeparvovec-xioi) approval documentation.
[4] EvaluatePharma. (2023). Oncology and Rare Disease Market Analysis.
